Afamelanotide in fair-skinned Parkinson’s patients
CLINUVEL has announced a new clinical program to evaluate afamelanotide as a treatment for early-stage Parkinson's Disease (PD) in fair-skinned patients. This innovative study aims to determine if afamelanotide can lower α-synuclein levels in blood and positively affect neurons in the midbrain through MC1R activation. The Phase IIa CUV901 study will involve six patients aged 40-85 and will assess the safety of afamelanotide while evaluating changes in blood α-synuclein levels and cognitive functions. Preclinical models have shown that afamelanotide could protect against α-synuclein toxicity, which is linked to neuron loss in PD. The trial has received ethics and regulatory approval, and patient enrolment is expected to start before the end of 2024.
- Initiation of a novel clinical program for afamelanotide in early-stage Parkinson's Disease.
- Afamelanotide has shown potential in lowering α-synuclein levels in preclinical models.
- Study targets fair-skinned patients, a high-risk group due to MC1R malfunction.
- Phase IIa CUV901 study focuses on safety and effectiveness, enhancing credibility.
- Regulatory and ethics approvals already obtained for the study.
- Eleven doses of afamelanotide planned over 56 days for comprehensive assessment.
- Study to only six patients, potentially affecting robustness of results.
- Afamelanotide's effectiveness in humans remains unproven, posing investment risks.
- Early-stage PD treatment; long-term benefits and side effects unknown.
- No current medicinal therapy for enrolled patients, potentially skewing results.
- Study duration and patient enrolment timeline could delay market impact.
Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s Disease
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients, and positively affect neurons of the midbrain. MC1R is known to be a key receptor in brain and skin cells.
In large studies, it was found that fair-skinned patients have a higher risk of PD associated with a malfunctioning MC1R.a, 1-2 Since afamelanotide is known to optimise the function of the MC1R, it is hypothesised that the drug treatment would have a positive effect in PD by lowering α-synuclein, as recently demonstrated in preclinical studies.²ˉ³ Afamelanotide is marketed in Europe and the USA as SCENESSE® for patients diagnosed with erythropoietic protoporphyria (EPP).
Evidence for use of afamelanotide in Parkinson’s Disease
Worldwide, individuals born with red hair and fair skin are found to have a loss of function of MC1Rs – expressed on skin and brain cells – and to carry an increased risk of Parkinson’s and melanoma.⁴¯⁵
In various Parkinson’s models it has been illustrated that an MC1R-binding drug – such as afamelanotide – enables cellular protection against α-synuclein, a toxic substance found in the neurons of PD patients. In preclinical models, the use of afamelanotide has been shown to improve neurodegenerative conditions.⁶
Following decades of human use, it has been well established that afamelanotide strongly binds to MC1R and optimises cellular functions (signalling) through pharmacological activation.
The CUV901 study is the first human study evaluating the effect of afamelanotide in PD as a therapeutic option.
Study design – CUV901
The Phase IIa CUV901 study will evaluate six fair-skinned patients with early symptoms of PD who are not yet receiving medicinal therapy.
The first objectives of the open-label study are to focus on the safety of afamelanotide, while determining α-synuclein in blood, and assessing visual changes in the midbrain. Secondary endpoints are to assess cognitive functions. The study design has obtained ethics and regulatory approval.b
Patients between 40 and 85 years old will receive 11 doses of 0.08 mg per kilogram body weight of afamelanotide on each day of drug administration, over a study duration of 56 days. The first patients are expected to enrol before the end of 2024.
Commentary
“We are immensely pleased to initiate a highly innovative study for afamelanotide,” CLINUVEL’s Chief Scientific Officer, Dr Dennis Wright said. “It marks a real breakthrough to conduct this study in Parkinson’s after lengthy regulatory discussions and preparation.
“At the heart of the problem in Parkinson’s lies the loss of dopamine producing neurons in the brain due to toxicity caused by α-synuclein. There is now evidence that afamelanotide – by binding to MC1R – could maintain stability and integrity of the affected neurons and slow down progression of the disorder.
“By analysing blood and brain scans of the substantia nigra, we will learn of afamelanotide’s potential effect in Parkinson’s. The ability to do something for this group of patients results from decades of clinical research and a focus on translating inhouse knowledge,” Dr Wright concluded.
About Parkinson’s Disease
Parkinson’s Disease is a progressive and degenerative disorder caused by oxidative stress and neuroinflammation. Symptoms consist of progressive loss of motor functions and increased tremor, as well as dementia, depression, sleep disorders and a range of autonomic dysfunctions. Ultimately PD can result in adverse clinical outcomes, contributing to over 200,000 deaths annually.
PD is characterised by the loss of dopamine producing neurons predominantly in the substantia nigra (SN) of the brain, while a high accumulation is seen of the neurotoxin α-synuclein.
It is thought that treatment of patients with early symptoms provides a better prognosis.
The current standard of care in PD is levodopa, monoamine oxidase B (MAO-B) inhibitors or dopamine agonists, which all aim to provide symptomatic relief but are not able to slow neurodegeneration. These medications become less effective as the disease progresses and escalating doses may be required.
Notes
a Epidemiological analyses from 120,000 US individuals revealed that fair skinned Parkinson’s patients have an increased risk of developing melanoma in a lifetime, both populations carrying a defective MC1R function.1 Afamelanotide is known to possess very high binding property (agonist) to MC1R and offer cellular protection by overcoming a loss-of-function of the receptor in patients with fair skin with red hair phenotype.
b Alpha-synuclein (α-synuclein) – as a measure of disease progress - is used as a biomarker in blood samples of PD patients.
References
- Gao, X., et al. (2009). Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol. 65:76–82.
- Chen, X., et al. (2017). The Melanoma-Linked “Redhead” MC1R Influences Dopaminergic Neuron Survival. Annals of Neurology, 81(3), 395–406.
- Chen, X., et al. (2017). Red hair, MC1R variants, and risk for Parkinson’s disease – a meta‐analysis. Annals of Clinical and Translational Neurology, 4(3), 212–216.
- Gao, X., et al. (2009). Family history of melanoma and Parkinson disease risk. Neurology 73:1286–1291.
- Kareus, S.A., et al. (2012). Shared Predispositions of Parkinsonism and Cancer: a Population-Based Pedigree-Linked Study. Arch Neurol. 69:1572–1577.
- Cai, W., et al. (2022). Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease. Molecular Neurodegeneration, 17(1), 16.
Srivast, P., et al. (2023). Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson’s disease. Research Square, rs.3.rs-3042571.
About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.
CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to https://www.clinuvel.com.
Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.
Head of Investor Relations
Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD
Investor Enquiries
https://www.clinuvel.com/investors/contact-us
Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Please see the full statement at https://www.clinuvel.com/2024/06/afamelanotide-in-fair-skinned-parkinsons-patients-20240618/.
Contact:
Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: mail@clinuvel.com
Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia
FAQ
What is the focus of CLINUVEL's new clinical program regarding afamelanotide?
What does the CUV901 study intend to assess?
When is patient enrolment for the CUV901 study expected to begin?
How many patients will be involved in the CUV901 study?
What is afamelanotide hypothesized to do in Parkinson's Disease patients?
